MetaCap

Aytu BioPharma (AYTU) vs Nasus Pharma (NSRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed Nasus Pharma (NSRX) over the past year, gaining 32.3% versus a loss of 68.4%. Aytu BioPharma is the larger company by market cap ($28.9 million vs $26.8 million), about 1.1 times the size. Nasus Pharma converts more of its revenue into profit, with a net margin of -0.5% versus -24.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%NSRX-68.41%
+50%-14%-78%
Nov 21, 20251 yearNov 20, 2026
AYTU+20.36%NSRX-71.73%
+30%-24%-78%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus NSRX key metrics
MetricAYTUNSRX
Share price$2.66$2.29
Market cap$28.91M$26.82M
1-day change0.00%-10.20%
YTD return+2.31%-74.97%
1-year return+32.34%-68.41%
5-year return-93.21%—
Forward P/E17.16—
EPS (TTM)$-1.78$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M$1.24B
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-5.86M
Gross margin63.95%—
Operating margin-14.44%-0.40%
Net margin-24.76%-0.47%
52-week high$3.07$9.50
52-week low$1.75$1.98
Distance from 52-week high-13.36%-75.89%
Analyst consensusstrong_buybuy
Avg. price target upside+263.53%+758.95%
Average volume141.18K16.80K
Shares outstanding10.87M11.71M
Employees757
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed NSRX by 100.8 percentage points over the past year.
  • Nasus Pharma is more profitable, keeping -0.5 cents of every revenue dollar as net income versus -24.8 cents for Aytu BioPharma.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

AYTU vs NSRX FAQ

Which is bigger, Aytu BioPharma or Nasus Pharma?

Aytu BioPharma (AYTU) is larger, with a market capitalization of $28.91M compared with $26.82M for Nasus Pharma (NSRX).

Which stock has performed better over the past year, AYTU or NSRX?

AYTU returned +32.34% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and Nasus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons